Elevated systemic XXXX and @entity6421 levels are associated with posttraumatic complications among @entity1 with multiple injuries: a prospective cohort study.

@entity1 @entity650 @entity295 @entity6421 @entity8923 @entity1850 @entity881 @entity687
INTRODUCTION: @entity1850 ( @entity1850 ), @entity295 and their subsequent complication, the @entity881 ( @entity881 ), remain major complications following polytrauma. This prospective clinical study aimed at evaluating the association between these and plasma @entity8923 ( @entity8923 ) and @entity6421 levels. METHODS: Inclusion in the series required an Injury Severity Score (ISS) >16, age 16-65 years, admission within 6 h of the accident and survival >48 h; 55 @entity1 were enrolled. Over 14 days, plasma @entity6421 and @entity8923 levels and the clinical course regarding @entity881 , @entity1850 and @entity295 were recorded daily using the Marshall Score for @entity881 and the ACCP/SCCM criteria for @entity1850 and @entity295 . RESULTS: @entity6421 and @entity8923 plasma levels were increased in + @entity881 cases as compared with - @entity881 cases over almost the entire observation period. @entity8923 concentrations over days 3-6 were significantly increased among @entity1 with @entity295 . These increases were all apparent 2-3 days before the clinical diagnosis of @entity295 or @entity881 was made. In contrast, no significant differences in @entity6421 and @entity8923 plasma levels were observed between @entity1 with and without @entity1850 . CONCLUSIONS: Determinations of @entity6421 and @entity8923 concentrations might represent early markers for posttraumatic complications such as @entity881 and @entity295 . They might help to differentiate between @entity1850 and @entity295 and thereby guide the timing of the surgery for polytrauma. @entity6421 and @entity8923 levels should be used together with the clinical status and other inflammatory markers ( @entity650 , @entity687 , etc.) for prediction of posttraumatic complications.
